No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
IMVT240816C31000
- 1.25
- -0.05-3.85%
15min DelayTrading Jul 22 09:59 ET
1.41High1.25Low
1.41Open1.30Pre Close3 Volume35 Open Interest31.00Strike Price391.00Turnover78.65%IV14.32%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier25DDays to Expiry1.25Extrinsic Value100Contract SizeAmericanOptions Type0.3720Delta0.0643Gamma19.13Leverage Ratio-0.0451Theta0.0064Rho7.11Eff Leverage0.0283Vega
Intraday
- 5D
- Daily
News
Immunovant Insider Sold Shares Worth $257,888, According to a Recent SEC Filing
Peter Salzmann, Director, Chief Executive Officer, on July 17, 2024, sold 8,685 shares in Immunovant (IMVT) for $257,888. Following the Form 4 filing with the SEC, Salzmann has control over a total
Buy Rating Affirmed for Immunovant Amidst Market Expansion and Promising Clinical Trials
Immunovant (IMVT) Down 1.6% Since Last Earnings Report: Can It Rebound?
LifeSci Capital Maintains Immunovant(IMVT.US) With Buy Rating, Maintains Target Price $52
LifeSci Capital analyst Sam Slutsky maintains $Immunovant(IMVT.US)$ with a buy rating, and maintains the target price at $52.According to TipRanks data, the analyst has a success rate of 47.4% and a t
We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate
We can readily understand why investors are attracted to unprofitable companies. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring reve
Immunovant Is Maintained at Outperform by Oppenheimer
Immunovant Is Maintained at Outperform by Oppenheimer
Comments
» Holdings: 112
» Holdings in Top 20: 58.46%
» Qtr over Qtr Change**: 28.47%
Top Holdings:
$Cerevel Therapeutics Holdings(CERE.US$
$Amicus Therapeutics(FOLD.US$
$Iovance Biotherapeutics(IOVA.US$
$Arcellx(ACLX.US$
$Nuvalent(NUVL.US$
$Apogee Therapeutics(APGE.US$
$Inhibrx(INBX.US$
$Fusion Pharmaceuticals(FUSN.US$
$Rhythm Pharmaceuticals(RYTM.US$
$Vaxcyte(PCVX.US$
$Soleno Therapeutics(SLNO.US$
$Medtronic(MDT.US$
$Madrigal Pharmaceuticals(MDGL.US$
...
» Holdings in Top 20: 58.46%
» Qtr over Qtr Change**: 28.47%
Top Holdings:
$Cerevel Therapeutics Holdings(CERE.US$
$Amicus Therapeutics(FOLD.US$
$Iovance Biotherapeutics(IOVA.US$
$Arcellx(ACLX.US$
$Nuvalent(NUVL.US$
$Apogee Therapeutics(APGE.US$
$Inhibrx(INBX.US$
$Fusion Pharmaceuticals(FUSN.US$
$Rhythm Pharmaceuticals(RYTM.US$
$Vaxcyte(PCVX.US$
$Soleno Therapeutics(SLNO.US$
$Medtronic(MDT.US$
$Madrigal Pharmaceuticals(MDGL.US$
...
8
$SPDR S&P Biotech ETF(XBI.US$
$Merck & Co(MRK.US$ x $Immunovant(IMVT.US$
$Eli Lilly and Co(LLY.US$ x $Cytokinetics(CYTK.US$ (and soon)
$Regeneron Pharmaceuticals(REGN.US$ x $Apellis Pharmaceuticals(APLS.US$ (panache & brash)
$Gilead Sciences(GILD.US$ x % $Madrigal Pharmaceuticals(MDGL.US$ (liver king)
$Bristol-Myers Squibb(BMY.US$ x $Iovance Biotherapeutics(IOVA.US$ (cell Tx boost needed)
$Eli Lilly and Co(LLY.US$ x $Merus(MRUS.US$ (partner n...
$Merck & Co(MRK.US$ x $Immunovant(IMVT.US$
$Eli Lilly and Co(LLY.US$ x $Cytokinetics(CYTK.US$ (and soon)
$Regeneron Pharmaceuticals(REGN.US$ x $Apellis Pharmaceuticals(APLS.US$ (panache & brash)
$Gilead Sciences(GILD.US$ x % $Madrigal Pharmaceuticals(MDGL.US$ (liver king)
$Bristol-Myers Squibb(BMY.US$ x $Iovance Biotherapeutics(IOVA.US$ (cell Tx boost needed)
$Eli Lilly and Co(LLY.US$ x $Merus(MRUS.US$ (partner n...
4
Insider selling of shares when the price was below the current rate raises eyebrows. The recent trend of insiders selling shares might worry investors, despite insiders owning about 0.6% of company shares, implying some shareholder alignment.
1 | Below is a look at the top insider trades with the biggest value in the past week.
One of $Immunovant(IMVT.US$'s directors and more than 10% owner, $Roivant Sciences(ROIV.US$, recently undertook a vast buy transaction worth $58 million. IMVT stock has gained over 104% since the start of this year. It is worth mentioning that Immunovant is a subsidiary of Roivant Sci...
One of $Immunovant(IMVT.US$'s directors and more than 10% owner, $Roivant Sciences(ROIV.US$, recently undertook a vast buy transaction worth $58 million. IMVT stock has gained over 104% since the start of this year. It is worth mentioning that Immunovant is a subsidiary of Roivant Sci...
6
$Immunovant(IMVT.US$ surged after the company announced positive initial results from both cohorts, the single-ascending dose (SAD) portion and the multiple-ascending dose (MAD) portion of its early-stage study of IMVT-1402.
One of the thing I look out for this stock is its debt in the balance sheet, it only have 10% of its total asset, but question remain whether they would be able to sustain cash burn before they turn profitable or rather when will their cash...
One of the thing I look out for this stock is its debt in the balance sheet, it only have 10% of its total asset, but question remain whether they would be able to sustain cash burn before they turn profitable or rather when will their cash...
+1
Read more